AryoGen

AryoGen Pharmed (Persian: آریوژن فارمد‎) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.[1][2][3]

AryoGen
TypePrivate Company
IndustryPharmaceutical
Founded2009
Headquarters
Tehran
,
Iran
Area served
Worldwide
Key people
Dr. Fereidoun Mahboudi
Chairman
Productsbiopharmaceuticals, Monoclonal antibody
Revenue US$ 100 million
Number of employees
 300+ (2015)
WebsiteAryoGen

History

AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was created by a group of scientific experts spun off a well versed Biopharmaceutical company, which formed a totally new entity christened as AryoGen Pharmed which started its production in 2011. It was deemed an issue of national interest due to the importance of the target products on Iran's community health care system, as well as its impact in the region and around the world.

AryoGen is the world's first company to produce biosimilar Blood Coagulation Factor VII, which required a 50 million Euros product investment. Also AryoGen has established a monoclonal antibody production line, making it one of only 10 manufacturers in the world.

AryoGen changed its name to AryoGen Pharmed in 2016.

AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified.[4]

Inside Aryogen, production line for AryoSeven

Products

AryoGen's products include:

  • Blood Coagulation factor VII with the name of AryoSeven which is a biosimilar form of Novoseven with multi billion dollars world market and is used for hemophilia patients and other conditions
  • Altebrel with the generic name of Etanercept and original trade name of Enbrel which for some years was the no. one in the biopharmaceutical market and is used for treatment of autoimmune diseases
  • Zytux with the generic name of Rituximab and original trade name of Rituxan which is an anticancer biomedicine,
  • َAryoTrust with the generic name of trastuzumab and original name of Herceptin which is a revolutionary drug in treatment of breast cancer
  • Stivant with the generic name of bevacizumab and original trade name of Avestin and is used for treatment of some sort of cancer.

AryoSeven is now approved by Iranian food and drug organisation and from Aug 2012 is in the market and other biomedicines are closing to the market.

AryoGen Pharmed Complex.

See also

References
  1. "IRAN, ISLAMIC REPUBLIC OF : Aryogen produces locally made medicines in Iran; helps Iran save up to $100 mln annually". Mena Report. Archived from the original on 2014-10-01.
  2. World's 2nd factor VII factory opened in Iran. - Mehr News Agency (MNA) | HighBeam Research
  3. Iran launches domestic manufacture of anti-hemophilia drug - Trend.Az
  4. "MENA mAb manufacturer AryoGen receives EU GMP approval / Pharma News / Home - GaBI Online - Generics and Biosimilars Initiative". www.gabionline.net. Retrieved 2019-06-11.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.